A Study on the Correlation Between MDR1 Polymorphism and Clopidogrel Resistance in Hui Patients Treated with Percutaneous Coronary Intervention

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2021 Mar 4

PMID 33658839

Citations 2

Authors

Fang Chen

Jing Zhang

Cheng-Xue Bian

Jian Zhang

Xiang-Bin Xin

Yang-Yang Pan

Xuan Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: This study assesses the correlation between MDR1 gene polymorphism and clopidogrel resistance (CR) in Hui patients with coronary heart disease (CHD) who were treated with percutaneous coronary intervention (PCI).

Methods: The study includes 204 Ningxia Hui patients with CHD who were treated with PCI. These patients were divided into two groups: those who with CR and others were non-clopidogrel resistant (NCR), according to the results of the patients' platelet aggregation rate, which was tested by adenosine diphosphate-induced turbidimetry on the second postoperative day. C3435T and C1236T genotypes and alleles were tested by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Results: The CR rate was 24.0%, and there were 3 genotypes of C3435T and C1236T. For C3435T, the distribution frequency of the 3435TT genotype and T allele was significantly higher in the CR group than in the NCR group. For C1236T, no significant difference was found between the two groups.

Conclusion: Hui patients who had CHD were treated with PCI. CR was most likely to occur in those who had the T allele of MDR1 in gene C3435T.

Citing Articles

The association between abcb1 gene polymorphism and clopidogrel response variability in stroke ischemic: a cross sectional study.

Hidayat R, Nabilah R, Fisher M, Aninditha T, Kurniawan M, Estiasari R BMC Neurol. 2024; 24(1):216.

PMID: 38914966 PMC: 11194867. DOI: 10.1186/s12883-024-03723-y.

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).

Akkaif M, Daud N, Shaaban A, Ng M, Kader M, Mohamed Noor D Molecules. 2021; 26(7).

PMID: 33915807 PMC: 8036376. DOI: 10.3390/molecules26071987.

References

Karazniewicz-Lada M, Danielak D, Rubis B, Burchardt P, Komosa A, Lesiak M . Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. J Clin Pharm Ther. 2014; 40(2):226-31. DOI: 10.1111/jcpt.12236. View

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2008; 360(4):363-75. DOI: 10.1056/NEJMoa0808227. View

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J . Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010; 121(4):512-8. DOI: 10.1161/CIRCULATIONAHA.109.885194. View

Mega J, Close S, Wiviott S, Shen L, Walker J, Simon T . Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010; 376(9749):1312-9. PMC: 3036672. DOI: 10.1016/S0140-6736(10)61273-1. View

Barragan P, Bouvier J, Roquebert P, Macaluso G, Commeau P, Comet B . Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003; 59(3):295-302. DOI: 10.1002/ccd.10497. View

Li Y, Tang H, Hu Y, Xie H . The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost. 2011; 10(2):199-206. DOI: 10.1111/j.1538-7836.2011.04570.x. View

Li Y, Wang Y, Li Y, Yang L . MDR1 gene polymorphisms and clinical relevance. Yi Chuan Xue Bao. 2006; 33(2):93-104. DOI: 10.1016/S0379-4172(06)60027-9. View

Sun W, Li Y, Li J, Zhang Z, Zhu W, Liu W . Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets. 2014; 26(6):558-62. DOI: 10.3109/09537104.2014.953044. View

Pare G, Mehta S, Yusuf S, Anand S, Connolly S, Hirsh J . Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010; 363(18):1704-14. DOI: 10.1056/NEJMoa1008410. View

10.

Tiroch K, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, Schomig A . Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010; 160(3):506-12. DOI: 10.1016/j.ahj.2010.06.039. View

11.

Carlquist J, Knight S, Horne B, Huntinghouse J, Rollo J, Muhlestein J . Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost. 2013; 109(4):744-54. DOI: 10.1160/TH12-05-0336. View

12.

Bliden K, DiChiara J, Tantry U, Bassi A, Chaganti S, Gurbel P . Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol. 2007; 49(6):657-66. DOI: 10.1016/j.jacc.2006.10.050. View

13.

Pedersen R, Nielsen F, Stage T, Vinholt P, el Achwah A, Damkier P . CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. Clin Exp Pharmacol Physiol. 2014; 41(11):870-8. DOI: 10.1111/1440-1681.12297. View

14.

Gutierrez-Rubio S, Quintero-Ramos A, Duran-Cardenas A, Franco-Topete R, Castro-Cervantes J, Oceguera-Villanueva A . 1236 C/T and 3435 C/T polymorphisms of the ABCB1 gene in Mexican breast cancer patients. Genet Mol Res. 2015; 14(1):1250-9. DOI: 10.4238/2015.February.13.3. View

15.

Kim R, Leake B, Choo E, Dresser G, Kubba S, Schwarz U . Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001; 70(2):189-99. DOI: 10.1067/mcp.2001.117412. View

16.

Liu Y, Liu N . [Clinical impact and underlying mechanism of clopidogrel response variability]. Zhonghua Xin Xue Guan Bing Za Zhi. 2010; 38(8):759-62. View

17.

Juliano R, Ling V . A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976; 455(1):152-62. DOI: 10.1016/0005-2736(76)90160-7. View

18.

Bonello L, De Labriolle A, Scheinowitz M, Lemesle G, Roy P, Steinberg D . Emergence of the concept of platelet reactivity monitoring of response to thienopyridines. Heart. 2009; 95(15):1214-9. DOI: 10.1136/hrt.2008.152660. View